加齢黄斑変性(AMD)の世界市場予測・分析:種類別・地域別

◆英語タイトル:Age-Related Macular Degeneration (AMD) Therapeutics Market by Type and Geography - Global Forecast 2019-2023
◆商品コード:IRTNTR31580
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年6月28日
◆ページ数:125
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア、ヨーロッパ、北米、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、加齢黄斑変性(AMD)の世界市場について調べ、加齢黄斑変性(AMD)の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、加齢黄斑変性(AMD)の市場規模をセグメンテーション別(種類別(湿式AMD、乾式AMD)、)と地域別(アジア、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は加齢黄斑変性(AMD)の世界市場規模が2019-2023期間中に年平均8%成長すると予測しています。
・サマリー
・レポートの範囲
・加齢黄斑変性(AMD)の市場状況
・加齢黄斑変性(AMD)の市場規模
・加齢黄斑変性(AMD)の市場予測
・加齢黄斑変性(AMD)の世界環境:ファイブフォース分析
・市場セグメンテーション:種類別(湿式AMD、乾式AMD)
・加齢黄斑変性(AMD)の顧客状況
・主要地域別市場規模:アジア、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Age-Related Macular Degeneration (AMD) Therapeutics Market: About this market

Age-related macular degeneration (AMD) is a bilateral ocular disease that affects the central area of the retina known as the macula. Technavio’s age-related macular degeneration considers sales from both wet AMD, dry AMD. Our analysis also considers the sales of AMD in Asia, Europe, North America and ROW. In 2018, the wet AMD segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increasing use of VEGF inhibitors, which are used for the treatment of wet AMD will play a significant role in the wet AMD segment to maintain its market position. Also, our global age-related macular degeneration market report also looks at factors such as high prevalence of AMD, strong pipeline and expected approvals, and rising geriatric populations. However, lack of approved therapies for dry AMD, introduction of biosimilars, side effects of available therapeutics may hamper the growth of the age-related macular degeneration industry over the forecast period.

Global Age-Related Macular Degeneration (AMD) Therapeutics Market: Overview

High prevalence of AMD

The prevalence of AMD is extremely high, owing to the presence of high-risk factors for developing the condition. Risk factors such as aging, smoking, high cholesterol, and high blood pressure are the major contributors to the development of AMD. Moreover, despite the high prevalence of AMD, no approved therapies are available in the market for the treatment of the condition. Thus, the high prevalence coupled with the huge unmet medical need of dry AMD is expected to drive the market at a CAGR of over 8% during the forecast period.

Development of gene therapy for AMD

There is a huge unmet need for safe and novel drugs to treat AMD. The currently available anti-VEGF therapies require repetitive and inconvenient intraocular injections. Owing to factors such as inconvenience and discomfort associated with frequent injections in the eye, patient compliance is a significant concern with anti-VEGF therapies. Hence, several companies are working on novel drugs against AMD, among which gene therapy is expected to cure the disease effectively. Hence, the development of gene therapy is expected to be a positive trend for the global AMD therapeutics market.

For the detailed list of factors that will drive the global age-related macular degeneration (and) therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of few major players, the global age-related macular degeneration (AMD) therapeutics market is moderately concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading age-related macular degeneration manufacturers, that include Amgen Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Regeneron Pharmaceuticals Inc.

Also, the age-related macular degeneration market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Wet AMD – Market size and forecast 2018-2023

Dry AMD – Market size and forecast 2018-2023

Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Strategic alliances

Development of gene therapy for AMD

Growing awareness about AMD

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Amgen Inc.

Bausch Health Companies Inc.

F. Hoffmann-La Roche Ltd.

Novartis AG

Regeneron Pharmaceuticals Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market

Exhibit 02: Segments of global pharmaceuticals market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Type – Market share 2018-2023 (%)

Exhibit 18: Comparison by type

Exhibit 19: Wet AMD – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: Wet AMD – Year-over-year growth 2019-2023 (%)

Exhibit 21: Dry AMD – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Phase III drugs for dry AMD

Exhibit 23: Cell therapies under development for dry AMD

Exhibit 24: Dry AMD – Year-over-year growth 2019-2023 (%)

Exhibit 25: Market opportunity by type

Exhibit 26: Customer landscape

Exhibit 27: Market share by geography 2018-2023 (%)

Exhibit 28: Geographic comparison

Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 30: North America – Year-over-year growth 2019-2023 (%)

Exhibit 31: Top 3 countries in North America

Exhibit 32: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 33: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 34: Top 3 countries in Europe

Exhibit 35: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 36: Population aged 65 years and above (% of total) in Asia 2017

Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 38: Top 3 countries in Asia

Exhibit 39: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 40: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 41: Top 3 countries in ROW

Exhibit 42: Key leading countries

Exhibit 43: Market opportunity

Exhibit 44: Some late-stage drugs for treatment of AMD

Exhibit 45: Global growth in geriatric population 2013-2017 (%)

Exhibit 46: Approximate cost of AMD drugs

Exhibit 47: Companies developing biosimilars: Overview

Exhibit 48: Side effects associated with drugs used for AMD

Exhibit 49: Impact of drivers and challenges

Exhibit 50: Vendor landscape

Exhibit 51: Landscape disruption

Exhibit 52: Vendors covered

Exhibit 53: Vendor classification

Exhibit 54: Market positioning of vendors

Exhibit 55: Amgen Inc. – Vendor overview

Exhibit 56: Amgen Inc. – Business segments

Exhibit 57: Amgen Inc. – Organizational developments

Exhibit 58: Amgen Inc. – Geographic focus

Exhibit 59: Amgen Inc. – Key offerings

Exhibit 60: Amgen Inc. – Key customers

Exhibit 61: Bausch Health Companies Inc. – Vendor overview

Exhibit 62: Bausch Health Companies Inc. – Business segments

Exhibit 63: Bausch Health Companies Inc. – Organizational developments

Exhibit 64: Bausch Health Companies Inc. – Geographic focus

Exhibit 65: Bausch Health Companies Inc. – Segment focus

Exhibit 66: Bausch Health Companies Inc. – Key offerings

Exhibit 67: Bausch Health Companies Inc. – Key customers

Exhibit 68: F. Hoffmann-La Roche Ltd. – Vendor overview

Exhibit 69: F. Hoffmann-La Roche Ltd. – Business segments

Exhibit 70: F. Hoffmann-La Roche Ltd. – Organizational developments

Exhibit 71: F. Hoffmann-La Roche Ltd. – Geographic focus

Exhibit 72: F. Hoffmann-La Roche Ltd. – Segment focus

Exhibit 73: F. Hoffmann-La Roche Ltd. – Key offerings

Exhibit 74: F. Hoffmann-La Roche Ltd. – Key customers

Exhibit 75: Novartis AG – Vendor overview

Exhibit 76: Novartis AG – Business segments

Exhibit 77: Novartis AG – Organizational developments

Exhibit 78: Novartis AG – Geographic focus

Exhibit 79: Novartis AG – Segment focus

Exhibit 80: Novartis AG – Key offerings

Exhibit 81: Novartis AG – Key customers

Exhibit 82: Regeneron Pharmaceuticals Inc. – Vendor overview

Exhibit 83: Regeneron Pharmaceuticals Inc. – Business segments

Exhibit 84: Regeneron Pharmaceuticals Inc. – Organizational developments

Exhibit 85: Regeneron Pharmaceuticals Inc. – Geographic focus

Exhibit 86: Regeneron Pharmaceuticals Inc. – Key offerings

Exhibit 87: Regeneron Pharmaceuticals Inc. – Key customers

Exhibit 88: Validation techniques employed for market sizing

Exhibit 89: Definition of market positioning of vendors



【掲載企業】

Amgen Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Regeneron Pharmaceuticals Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[加齢黄斑変性(AMD)の世界市場予測・分析:種類別・地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆